Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Canton Strategic Holdings (CNTN) · oqro.io/stocks/CNTN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Canton Strategic Holdings insider trading
Have Canton Strategic Holdings insiders bought shares recently?
No open-market purchase by an insider of Canton Strategic Holdings was filed in the last 90 days. The latest on record was on Jun 24, 2025.
How often do Canton Strategic Holdings insiders buy and sell shares?
Since 2022, Canton Strategic Holdings insiders reported 26 open-market purchases and 8 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2025.
Who is selling Canton Strategic Holdings stock?
No open-market sale by an insider of Canton Strategic Holdings (CNTN) was filed with the SEC in the last 90 days.
Do members of Congress trade CNTN?
No trade in Canton Strategic Holdings (CNTN) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−75.6% (−$3.74) from Feb 18, 2026 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $4.95 on Feb 18, 2026 to $1.21 on Nov 20, 2026 (−75.6%). Disclosed in this range: 8 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 5 13F position changes for 3 quarters ending in it.
$0$2$3$4$5$6$1.21
MarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 8 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Finance Services company based in New York, Ny.
Last 12 months
Not enough history
Market value
$98M
Close of Nov 19, 2026 × shares outstanding (per ADS where it applies)
Short interest: 8.16M shares sold short (10.2% of shares outstanding), +1.6% vs the previous count, 12.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
2 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Since Feb 18, 2026, CNTN is down 75.2% and the index fund is up 4.3%: 79 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much CNTN moves
A usual day
±3.6%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
14.1%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−17.5%Jun 24, 2026
Largest one-day rise
+15.2%Jun 8, 2026
Deepest fall of the year
−76.1%From the close of Mar 2, 2026 to Nov 19, 2026.
Days of 5% or more
64Out of 191 sessions, in either direction.
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Insider buying and selling since 2022
Insiders of Canton Strategic Holdings reported 26 open-market purchases and 8 sales since 2022; purchases in 4 different years, most recently 2025.
Year
Bought
Sold
2026
—
$344K8×8 trades
2025
$593K5×5 trades
—
2024
$35K6×6 trades
—
2023
$25K2×2 trades
—
2022
$104K13×13 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Red flags in its filings
Jan 15
Notice of delisting or failure to meet listing rules
“Sireesh Appajosyula, who will step down from the role of Interim Chief Financial Officer and will continue to serve as the Chief Executive Officer of Gravitas Life Sciences, Inc., a subsidiary of the Company.”
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Canton Strategic Holdings filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 8 open-market sales (about $344K, in 1 filing, by 1 person). One Form 4 can list many transactions. In the 12 months before that, they filed 6 open-market purchases (about $603K, in 5 filings) and 0 open-market sales (about $0, in 0 filings). (Canton Strategic Holdings on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 3 new or larger positions and 3 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for CNTN on the settlement date of Oct 30, 2026 was 8,163,137 shares (+1.64% on the previous report), about 12.59 days of average volume. In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: ARK Investment Management (reduced, 410,669 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Canton Strategic Holdings filed a Form 8-K on Jul 23, 2026 (Items 1.01, 2.01, 8.01) that OQRO classes as: completed buying or selling a business or assets, and signed an important agreement (and 1 more item). The company's own opening sentence of that report reads: "On July 23, 2026, the Company issued a press release announcing the closing of the Transaction. The press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference."
Who holds it. 68 funds reported a stake in Canton Strategic Holdings in their 13F for Q2 2026. The largest by value: ARK Investment Management LLC (17.8% of the value reported), BlackRock, Inc. (17.8% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (14.7% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Canton Strategic Holdings filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 8 open-market sales (about $344K, in 1 filing, by 1 person). One Form 4 can list many transactions.
In the 12 months before that, they filed 6 open-market purchases (about $603K, in 5 filings) and 0 open-market sales (about $0, in 0 filings).
The largest sale: Gary S. Stetz, Director, about $51K, filed May 27, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 3 new or larger positions and 3 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for CNTN on the settlement date of Oct 30, 2026 was 8,163,137 shares (+1.64% on the previous report), about 12.59 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: ARK Investment Management (reduced, 410,669 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Canton Strategic Holdings filed a Form 8-K on Jul 23, 2026 (Items 1.01, 2.01, 8.01) that OQRO classes as: completed buying or selling a business or assets, and signed an important agreement (and 1 more item).
The company's own opening sentence of that report reads: "On July 23, 2026, the Company issued a press release announcing the closing of the Transaction. The press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference."
Canton Strategic Holdings filed a Form 8-K on Feb 6, 2026 (Items 5.02, 7.01, 8.01) that OQRO classes as: changed a top executive or board member, and shared information with investors (and 1 more item).
The company's own opening sentence of that report reads: "On February 5, 2026, the Board of Directors (the ' Board ') of Tharimmune, Inc. (the ' Company ') appointed Angela Dominy Radkowski, age 37, as Chief Operating Officer of the Company, effective February 5, 2026 (the ' Effective D..."
Canton Strategic Holdings filed a Form 8-K on Jan 15, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange.
The company's own opening sentence of that report reads: "On January 9, 2026, Tharimmune, Inc. (the 'Company') received a notification letter from The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605 ('Rule 5605'), which requires, among other things, tha..."
Press coverage listed by Finnhub: "Canton Strategic Holdings’ Validator Scaling and LaaS Growth, Quarterly Update Report" (Yahoo, Nov 18, 2026).
Press coverage listed by Finnhub: "SEC Grants Canton Coin No-Action Relief, Recognizing Token as a Digital Commodity" (Yahoo, Nov 4, 2026).
Press coverage listed by Finnhub: "Institutional Tokenization Through the Canton Network, Initiation Report" (Yahoo, Nov 2, 2026).
CNTN closed at $1.34 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $1.69 to $1.34, a change of −21.0%.
Who holds it
68 funds reported a stake in Canton Strategic Holdings in their 13F for Q2 2026. The largest by value: ARK Investment Management LLC (17.8% of the value reported), BlackRock, Inc. (17.8% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (14.7% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Latest annual report filed Mar 31, 2026, compared with the one filed Mar 26, 2025. Read the filing
New risk factors in the latest annual report (27 headings)
We are shifting our business strategy from biotechnology operations to a CC treasury strategy, which represents a fundamental change in our risk profile and may not be successful.
Our digital asset treasury exposure to CC involves novel and significant risks, including market volatility, accounting, regulatory, custody, cybersecurity, liquidity and reputational risks, which could have a material adverse effect on our business, results of operations and financial condition.
Failure of the Canton Network to achieve broad market acceptance would materially and adversely affect our business, financial condition, and results of operations.
Regulatory change reclassifying CC as a security could lead to our classification as an “investment company” under the Investment Company Act of 1940, as amended, or the 1940 Act, and could adversely affect the market price of CC and the market price of our common stock.
Our financial results and the market price of our common stock may be affected by the prices of CC.
The concentration of CC ownership could increase the risk of malicious activity, including potential attacks on the Canton Network.
We face risks relating to the custody of our CC tokens, including the loss or destruction of private keys required to access our CC tokens and cyberattacks or other data loss relating to our CC tokens, including smart contract related losses and vulnerabilities.
We will operate in a highly competitive environment and will compete against companies and other entities with similar strategies, including companies with significant CC holdings and spot exchange traded funds and spot ETPs for digital assets.
And 19 more headings in the filing.
No longer listed (23 headings from the year before)
Finding appropriate biomarkers for our potential drug candidates could limit our commercialization prospects and cause our losses to continue.
We will require substantial additional funding. If we are unable to raise capital on favorable terms when needed, we could be forced to curtail, delay or discontinue our research or drug development programs or any future commercialization efforts.
Management has performed an analysis and concluded that there exists a substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing on terms acceptable to us, if at all.
If we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory approval could be delayed or prevented.
We may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our candidates prove to be ineffective, unsafe or commercially unviable, our pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.
We sometimes estimate, or may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies or clinical trials, the submission of regulatory filings, the receipt of marketing approval or the realization of other commercialization objectives.
Legal proceedings (Item 3)
From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Pandemics, such as COVID-19, may adversely impact our business, results of operations, financial condition, liquidity and cash flows and that of our clients.
We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.
And 15 more headings in the filing.
Latest results: quarter ending Sep 30, 2026
Revenue
$3.05M
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $26.9M, at Sep 30, 2026
Net income, last 12 months
−$131M
Operating loss: profit did not cover interest (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 16, 2026.
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 16, 2026. Quarterly reports are not audited. Read the filing
By product or service
Other Revenue$1.55M51%
No figure for the same quarter a year earlier
Network Validation Revenue$1.5M49%
No figure for the same quarter a year earlier
Total revenue$3.05M
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 4,000 words.
From “Overview”, in the company's words
During the year ended December 31, 2025, we began a strategic shift in our business to prioritize digital asset treasury management and investment in the digital asset ecosystem, specifically the Canton Network. As described in Item 1, from 2022 through late 2025, we primarily operated as a biotechnology company developing therapeutic candidates in inflammatory and immunologic conditions. In November 2025, we undertook a strategic shift to prioritize a disciplined digital asset treasury strategy. In connection with this shift, in November 2025 we completed a private placement offering, strengthening our liquidity and supporting our digital asset treasury strategy. Concurrently, we entered into an at-the-market equity program and established a shelf registration statement.
What the section covers (25 headings)
Overview
Components of Results of Operations
Revenue
Research and Development Expenses
General and Administrative Expenses
Interest Income
Unrealized Loss from Digital Asset Holdings
Results of Operations
Comparison of the Years Ended December 31, 2025 and 2024
Interest Expense
Unrealized Loss from Digital Assets Holdings
Liquidity and Capital Resources
Cash Flow Activities for the Years Ended December 31, 2025 and 2024
Cash Flows from Operating Activities
And 11 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026 and Form 10-Q filed Nov 16, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 46.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (11.9% on ATS, 34.1% with other brokers), above its 26-week average of 43.7%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: INTELLIGENT CROSS LLC (13.7%), MS POOL (ATS-4) (11.4%), UBS ATS (10.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.